Related by context. All words. (Click for frequent words.) 69 nab paclitaxel 69 treatment naïve genotype 68 ritonavir boosted 67 trastuzumab Herceptin R 67 orally administered inhibitor 67 lesinurad 66 evaluating tivozanib 66 AEG# 66 AEGR 66 JAK inhibitor 66 relapsed MM 66 ALN HPN 66 MAGE A3 ASCI 66 visilizumab 66 multicenter Phase II 65 sunitinib malate 65 PRTX 65 telaprevir VX 65 blinded randomized placebo controlled 65 plus Copegus R 65 docetaxel chemotherapy 65 pertuzumab 65 PRE SURGE 65 HCV SPRINT 65 LUX Lung 65 Phase Ib clinical 65 telaprevir dosed 65 oral prodrug 65 neratinib 65 Phase 1b trial 65 novel VDA molecule 65 virus HCV protease inhibitor 65 treatment naive genotype 65 investigational protease inhibitor 64 lexidronam injection 64 HGS# 64 nucleotide analog 64 PSMA ADC 64 phase IIb clinical 64 bevirimat Study 64 mertansine 64 MEK inhibitor 64 placebo controlled Phase 64 MSI #F 64 CIMZIA ™ 64 TMC# C# 64 Mg Usa 64 inhibitor RG# 64 tolerability pharmacokinetics 64 CIMZIA TM 64 Tyrima 64 Phase Ib II 64 pharmacokinetics PK 64 docetaxel Taxotere R 64 CRx 64 CYT# potent vascular disrupting 64 Valopicitabine 64 HCV protease inhibitor 64 pegylated interferon alfa 2a 64 oral deforolimus 64 MORAb 64 double blinded placebo 64 forodesine 64 elotuzumab 63 pharmacodynamic effects 63 non nucleoside inhibitor 63 fenofibric acid 63 Randomized Phase 63 lomitapide 63 cisplatin gemcitabine 63 Xelox 63 FOLFIRI chemotherapy 63 Randomized Double blind 63 antibody MAb 63 AAG geldanamycin analog 63 cilengitide 63 alvespimycin 63 Ozarelix 63 Elotuzumab 63 HZT 63 GW# [003] 63 HCV NS5B polymerase 63 pegylated liposomal doxorubicin 63 BRIM2 63 ZACTIMA 63 EQUIP OB 63 FOLFOX6 chemotherapy regimen 63 evaluating satraplatin 63 mg TID 63 AKT inhibitor 63 urate lowering 63 zonisamide SR 63 familial amyloidotic polyneuropathy FAP 63 investigational hepatitis C 63 rNAPc2 63 Traficet EN 63 Omacetaxine 63 davunetide intranasal AL 63 Xeloda ® 63 liposomal formulation 63 Initiate Phase 63 polymerase inhibitor 63 non nucleoside HCV 63 ceftazidime 63 oral rivaroxaban 63 bendamustine 63 oral Janus kinase 63 cyclophilin inhibitor 63 YONDELIS 62 Protease Inhibitor 62 phase IIa clinical 62 PI3K/Akt pathway inhibitor 62 oral antiviral 62 μg dose 62 Pertuzumab 62 metaglidasen 62 EOquin TM phase 62 OMP #M# 62 budesonide foam 62 phase IIIb 62 phase IIb trial 62 ENMD # 62 nucleoside analog 62 HuLuc# 62 sorafenib Nexavar ® 62 RE SURGE 62 tolerated dose MTD 62 RELOVAIR ™ 62 blind randomized placebo 62 SCH # 62 phase Ib 62 IMiDs ® 62 dexpramipexole 62 Imprime PGG 62 CCX# 62 LY# [002] 62 ritonavir boosted atazanavir 62 safety tolerability pharmacokinetic 62 MGd 62 Oral NKTR 62 randomized multicenter 62 pan HDAC inhibitor 62 oral ridaforolimus 62 Bezielle 62 INSPIRE Trial Phase III 62 standard chemotherapy regimen 62 Vidaza ® 62 PEG Interferon lambda 62 mycophenolate mofetil 62 solithromycin 62 multicenter Phase III 62 evaluating T DM1 62 alfa 2a 62 REMINYL ® 62 controlled multicenter Phase 62 safety tolerability pharmacokinetics 62 pharmacodynamic profile 62 pomalidomide 62 selective estrogen receptor modulator 62 regorafenib 62 optimal dosing 62 HuMax EGFr 62 Copegus ribavirin 62 investigational humanized monoclonal antibody 62 active comparator 62 Pegasys R 62 reslizumab 62 factorial design 62 metastatic hormone refractory 62 sorafenib Nexavar 62 acyclovir Lauriad R 62 vinca alkaloid 62 thymalfasin 62 bortezomib Velcade 62 Elvitegravir 62 Aflibercept 62 samarium Sm 62 ug dose 62 Phase III Pivotal 62 erlotinib Tarceva ® 62 receptor tyrosine kinase inhibitor 62 masked placebo controlled 62 chemotherapy FOLFOX 62 sorafenib tablets 62 prospective randomized placebo 61 CD3 monoclonal antibody 61 BRAF inhibitor 61 ToGA 61 mg RDEA# 61 plus gemcitabine 61 controlled multicenter 61 Phase Ib study 61 ascending dose 61 CIMZIA TM certolizumab pegol 61 HGS ETR1 mapatumumab 61 ExTRACT TIMI 61 phase IIb study 61 deforolimus 61 TPI ASM8 61 Panzem NCD 61 teriflunomide 61 CR# vcMMAE 61 registrational Phase 61 adecatumumab 61 genotypic resistance 61 celgosivir 61 viral kinetic 61 ascending dose study 61 JVRS 61 doripenem 61 Tezampanel 61 CANCIDAS 61 PDE4 inhibitor 61 VFEND 61 Initiated Phase 61 NXL# 61 hour bronchodilation 61 ACTEMRA TM 61 Trandolapril 61 Xeloda capecitabine 61 Halozyme Ultrafast Insulin 61 posaconazole 61 histone deacetylase inhibitor 61 Spiegelmer ® 61 Phase 1b clinical 61 peginterferon alfa 2a 61 Navelbine 61 CCR5 mAb 61 MKC# MKC# PP 61 multicenter randomized placebo controlled 61 CBLC# 61 dose escalation Phase 61 galiximab 61 MT# MEDI 61 APTIVUS 61 placebo controlled clinical 61 Teriflunomide 61 selective androgen receptor modulators 61 PREZISTA r 61 relapsed myeloma 61 DermaVir Patch 61 Phase Ib clinical trials 61 INCB# [003] 61 idraparinux 61 EGFR HER2 61 trastuzumab emtansine T DM1 61 CTA# Injection 61 evaluating Vectibix 61 huC# DM4 61 bortezomib Velcade R 61 TMC# r 61 HCV RESPOND 2 61 lapatinib Tykerb 61 selective modulator 61 thalidomide Thalomid 61 Pivotal Phase 61 COU AA 61 Velcade bortezomib 61 PRT# 61 Dapagliflozin 61 vorinostat 61 selective phosphodiesterase 61 Degarelix 61 ketolide antibiotic 61 Initiates Phase II 61 dexamethasone Decadron 61 Folfox 61 nucleoside polymerase inhibitor 61 Epothilone D 61 velafermin 61 radezolid 61 monoclonal antibody MAb 61 REG1 61 Neulasta R 61 darunavir ritonavir 61 vapreotide acetate 61 azathioprine monotherapy 61 HPTN 61 investigational HCV polymerase 61 Proellex TM 61 CCR5 antagonist 61 selective antagonist 61 RE LY ® 60 SinuNase ™ 60 ONTARGET 60 BMS # 60 2 inhibitor CYT# 60 Meets Primary Endpoint 60 plasma kallikrein inhibitor 60 prospective multicenter 60 PDX pralatrexate 60 KRAS mutations occur 60 protease inhibitor PI 60 Amplimexon 60 Tanespimycin 60 Pegasys ® 60 uricase 60 Parathyroid Hormone 60 LEXIVA r 60 blinded placebo controlled 60 Peg IFN 60 mg BID dose 60 boosted protease inhibitor 60 PEGASYS ® 60 corticosteroid dexamethasone 60 MYCAMINE 60 pharmacodynamic markers 60 phase III ACCLAIM 60 DUROS 60 preclinically 60 Ecallantide 60 CYT# QbG# 60 designated HVTN 60 initiated Phase Ib 60 INCB# [001] 60 Phase 1b clinical trials 60 maximally tolerated dose 60 Myocet 60 Enzastaurin 60 SAR# [002] 60 orally bioavailable mimics 60 PEGINTRON TM 60 vesicular monoamine transporter 60 daunorubicin 60 lumiliximab 60 Peginterferon Alfa 2a 60 long acting muscarinic 60 piperacillin tazobactam 60 perampanel 60 Azedra 60 PSN# [002] 60 sorafenib Nexavar R 60 beta2 agonist 60 selective androgen receptor modulator 60 metreleptin 60 pain palliation 60 paclitaxel poliglumex 60 multicenter Phase 60 brivaracetam 60 CDK inhibitor 60 recurrent glioblastoma multiforme 60 mapatumumab 60 Tarceva TM 60 Microplasmin 60 blind randomized controlled 60 GMX# 60 FOLOTYN ® 60 assessing T DM1 60 Camptosar ® 60 Allovectin 7 R 60 ISIS # 60 fostamatinib 60 amprenavir 60 Prospective Randomized 60 Fludara ® 60 induced macular edema 60 Darunavir 60 RSD# oral 60 histone deacetylase HDAC inhibitor 60 Mg Uk 60 bevacizumab Avastin ® 60 somatostatin analog 60 prucalopride 60 OncoVex 60 QD dosing 60 5 fluorouracil leucovorin 60 oral chemotherapeutic agent 60 angiotensin receptor blocker ARB 60 estramustine 60 rosuvastatin #mg 60 Phase III Clinical Trials 60 pegylated interferon alpha 60 fosbretabulin 60 tenofovir Viread 60 capecitabine Xeloda 60 Completes Patient Enrollment 60 sargramostim 60 EDEMA3 60 torezolid 60 5 FU leucovorin 60 placebo controlled Phase III 60 Gemzar ® 60 Angiotensin Converting Enzyme 60 mcg doses 60 Phase III randomized 60 Janus kinase 60 dose escalation trial 60 Phase IIIb clinical 60 Non Alcoholic Steatohepatitis 60 inhaled corticosteroid ICS 60 IMiDs ® compound 60 Prostate AdenoCarcinoma Treatment 60 docetaxel Taxotere 60 Maximum Tolerated Dose MTD 60 primary hypercholesterolemia 60 tipifarnib 60 Ceplene/IL-2 60 Vidaza R 60 novel topoisomerase 60 cinacalcet 60 Phase Ib 60 Rigel R# 60 Methylnaltrexone 60 refractory NSCLC 60 PRADAXA 60 arsenic trioxide injection 60 PNP inhibitor 60 rosuvastatin Crestor 60 Phase III Clinical Trial 60 Vascugel 60 inhibitor VX 60 ribavirin Copegus 60 Pafuramidine 60 trastuzumab DM1 T DM1 60 HCV replicon 60 Clinical Antipsychotic Trials 60 Sapacitabine 60 Ceflatonin R 60 evaluating carfilzomib 60 ongoing Phase 1b 60 immunotherapeutic agent 60 Peginterferon 60 PROSTVAC ® 60 antiviral efficacy 60 Obatoclax 59 IMiD 59 ZOLINZA 59 EXPLORE Xa 59 compound INCB# 59 GOUT 59 Xyfid TM 59 candesartan cilexetil 59 randomized Phase III 59 docetaxel Taxotere ® 59 highly selective inhibitor 59 Imprime PGG ® 59 saquinavir ritonavir 59 ARB telmisartan 59 XL# XL# XL# 59 class mGluR5 inhibitor 59 multicenter phase 59 aspirin clopidogrel 59 GetGoal Phase III 59 CEQ# 59 multicenter randomized 59 NS5B polymerase 59 Eraxis 59 nucleotide analogue 59 efficacy tolerability 59 orally inhaled migraine 59 lenalidomide Revlimid ® 59 Atripla combines 59 INC# 59 HeFH 59 aplindore 59 gemcitabine chemotherapy 59 dosage regimens 59 CD4 monoclonal antibody 59 PS# [001] 59 NSABP B 59 IGF 1R inhibitor 59 Phase IIb clinical trials 59 albiglutide 59 2 methoxyestradiol 59 lenalidomide dexamethasone 59 rapid virologic response 59 CXA 59 huN# DM1 59 colesevelam HCl 59 investigational oral 59 Deforolimus 59 blind randomized multicenter 59 evaluating mipomersen 59 abiraterone acetate 59 Antiviral Activity 59 double blinded randomized 59 DU #b 59 dosing cohorts 59 integrase inhibitor 59 label multicenter Phase 59 Empatic ™ 59 Sustiva efavirenz 59 dihydrochloride 59 Safinamide 59 Nanobody 59 R#/MEM # 59 eprotirome 59 Maribavir 59 BCR ABL inhibitors 59 peginterferon alpha 2a 59 Sym# 59 AAG KOS 59 serotonin norepinephrine reuptake inhibitor 59 Boceprevir 59 tipranavir 59 Phase III placebo controlled 59 selective adenosine 59 Phase 1b 59 trabedersen 59 EndoTAGTM 1 59 Phase Ia 59 favorable pharmacokinetic profile 59 q8h 59 sodium glucose cotransporter 59 lixisenatide 59 prospective randomized multicenter 59 antitumor effect 59 toenail onychomycosis 59 AVOREN 59 BARACLUDE R 59 enzastaurin 59 targeted radiotherapeutic 59 immunomodulator 59 Dasatinib 59 protein tyrosine phosphatase 1B 59 Panzem R 59 riociguat 59 ADP receptor antagonist 59 nitazoxanide 59 Nexavar ® 59 Diabetic Macular Edema 59 KB# [002] 59 nucleoside analogues 59 IMiDs 59 Androxal TM 59 Vidaza azacitidine 59 NOXAFIL 59 brivanib 59 topical gel formulation 59 TO AVOID PREGNANCY WHILE 59 azilsartan medoxomil 59 Actilon 59 TBC# 59 biologic DMARD 59 Pharmacokinetics PK 59 microgram kg 59 efavirenz emtricitabine 59 Genz # 59 HMG CoA reductase inhibitors 59 vicriviroc 59 systemic RNAi therapeutic 59 ALGRX 59 oral FTY# 59 refractory gout 59 LymphoStat B belimumab 59 investigational pharmacologically unique 59 TCAD therapy 59 idarubicin 59 PEG INTRON R 59 prospective observational 59 oral dual endothelin 59 pan histone deacetylase 59 radiolabeled monoclonal antibody 59 adalimumab Humira 59 rFSH 59 Ophena TM 59 ABSORB clinical 59 direct thrombin inhibitors 59 Intervention Effectiveness 59 fluvastatin 59 Staccato alprazolam 59 Phase IIa trials 59 HER2 positive metastatic breast 59 BAY #-# 59 HGS ETR2 59 By JENNIFER LEARN 59 MKC# MT 59 registrational trial 59 plus prednisone prednisolone 59 hyperphenylalaninemia HPA due 59 Pegasys plus Copegus 59 Genasense ® oblimersen 59 doxorubicin cyclophosphamide 59 HGS ETR1 59 NS5b 59 pitavastatin 59 placebo controlled randomized 59 ThermoDox R 59 Dose Ranging Study 59 relapsed refractory multiple myeloma 59 Phase 1a clinical 59 NCCTG 59 IMA# 59 pramlintide 59 NATRECOR ® 59 orally bioavailable 59 AZILECT R 59 TYGACIL 59 topically administered 59 ZYBRESTAT TM 59 CTAP# Capsules 59 ARCOXIA 59 Locked Nucleic Acid LNA 59 complement inhibitor eculizumab 59 Carotid Revascularization Endarterectomy vs. 59 Phase 2a trial 59 aflibercept 59 sulindac 59 Aplidin R 59 R sorafenib tablets 59 EZN 59 CRESTOR #mg 59 intranasal formulation 59 LHRH antagonists 59 PHX# 59 DEB# 59 Empatic 59 emtricitabine Emtriva 59 octreotide LAR 59 Cetrorelix pamoate 59 Blinatumomab 59 azacytidine 59 plus dexamethasone 59 nucleoside analogue 59 sulodexide 59 CA4P 59 Amrubicin 59 talabostat 59 Cloretazine ® 59 clinical pharmacology studies 59 IAP inhibitor 59 THR beta agonist 59 TG MV 59 COLAZAL R 59 Phase IIa trial 59 INGN 59 constipation OIC 59 selective kinase inhibitor 59 Hycamtin ® 59 CLL8 59 Zemplar Capsules 59 TRO# 59 dose escalation clinical 59 Glufosfamide 59 Elagolix 59 Afatinib 59 dasatinib Sprycel 58 Hsp# Inhibitor 58 Acute Ischemic Stroke 58 Xanafide 58 BENICAR HCT 58 STRIDE PD 58 Silodosin 58 metformin sulfonylurea 58 liposome encapsulated 58 indinavir Crixivan 58 Clonicel 58 ganetespib 58 LY# [003] 58 viral kinetics 58 Tesmilifene 58 LAB CGRP 58 ChronVac C R 58 ulimorelin 58 peginterferon alfa 2b 58 APPRAISE 58 Dabigatran etexilate 58 abacavir Ziagen 58 blinded randomized 58 CEROVIVE NXY 58 dextromethorphan quinidine 58 blind randomized 58 Vidofludimus 58 Resten NG 58 fallopian tube cancers 58 Cloretazine 58 CorVue ™ 58 Phase 2b study 58 Randomized Double Blind 58 Melphalan 58 acadesine 58 mGluR5 negative 58 ALN TTR 58 Varespladib 58 custirsen 58 Intervention Effectiveness CATIE 58 bevacizumab Avastin R 58 preclinical efficacy 58 Mipomersen 58 ORMD 58 PEG SN# 58 ertapenem 58 qualitative serum 58 PegIFN 58 PREZISTA ritonavir 58 HQK 58 PEGylated interferon beta 1a 58 Antiviral Therapy 58 DPP4 inhibitor 58 FOLFOX6 58 comparator arm 58 BCIRG 58 NVA# 58 COMBIVIR 58 #mg q8h 58 Betaferon R 58 interferon gamma 1b 58 methylnaltrexone bromide 58 weekly subcutaneous injections 58 CONQUER OB 58 icatibant 58 ImmunoGen TAP technology 58 melphalan prednisone 58 CYP#A# CYP#D# 58 selective agonist 58 clevidipine 58 diarrhea predominant irritable 58 PREZISTA rtv 58 transcriptase inhibitor NNRTI 58 acting muscarinic antagonist 58 Novel Oral 58 low dose ritonavir 58 unique alkylating agent 58 mg q#h 58 TACI Ig 58 LEVADEX 58 TG# [003] 58 Adalimumab 58 ASTEROID 58 investigational pan BCR 58 PEGylated Fab fragment 58 Controlled Trial 58 pathophysiological effects 58 efavirenz EFV 58 mg administered orally 58 flavopiridol 58 cathepsin K inhibitor 58 dasatinib Sprycel ® 58 CRLX# 58 NEUGENE 58 ascending doses 58 evaluating Xcytrin 58 nucleoside reverse transcriptase inhibitor 58 Vascular Wrap TM 58 developing Bicifadine serotonin 58 investigational antiplatelet agent 58 RezularTM 58 Factor VIIa 58 tipranavir r 58 antisense drug 58 Luteinizing Hormone Releasing Hormone 58 brand ciclesonide HFA 58 flurpiridaz F 58 midstage trials 58 Initiates Enrollment 58 selective orally bioavailable 58 lenalidomide Revlimid R 58 IRX 2 58 generation antisense 58 ARCALYST ® rilonacept 58 HCV protease inhibitors 58 XmAb# 58 paclitaxel Taxol ® 58 doxorubicin docetaxel 58 selective immunoproteasome inhibitor 58 Asentar 58 IV bolus 58 axitinib 58 REVIVE TA 58 placebo controlled studies 58 Nexavar sorafenib tablets 58 trodusquemine 58 low dose cytarabine 58 randomized controlled Phase 58 allosteric modulator NAM 58 relapsing multiple sclerosis 58 Multiple Ascending Dose 58 trastuzumab Herceptin ® 58 sunitinib Sutent ® 58 Dual Opioid 58 direct thrombin inhibitor 58 Phase #/#a 58 antisense inhibitors 58 TMC# [001] 58 Double Blind Randomized 58 Betaferon ® 58 Navelbine ® 58 Cethromycin 58 Trial Evaluating 58 neuroprotective properties 58 liposome injection 58 VISICOL R 58 GLPG# 58 ADAGIO study 58 opioid induced bowel dysfunction 58 myelofibrosis polycythemia vera 58 XL# anticancer compounds 58 symptomatic BPH 58 Vaxfectin TM adjuvant 58 cilostazol 58 CCR5 inhibitor 58 CD# monoclonal antibody 58 trials RCTs 58 RhuDex ® 58 gemcitabine carboplatin 58 Alagebrium 58 Tekturna HCT 58 Phase 2b clinical 58 Onconase 58 initiate Phase 1b 58 Panzem R NCD 58 triciribine phosphate monohydrate 58 P#X# antagonist 58 vidofludimus 58 Multimeric 58 Captisol Enabled 58 AZT zidovudine Retrovir 58 cetuximab Erbitux R 58 Cimzia TM 58 IL# PE#QQR 58 p# biomarker 58 APTIVUS r 58 Alocrest 58 #I TM# 58 iniparib 58 BRIM3 58 CORT # 58 markets COLAZAL 58 Phase IIb Trial 58 Phase 2a clinical 58 iobenguane 58 immunoconjugate 58 HSP# inhibitor 58 valopicitabine 58 imetelstat 58 PEG IFN 58 GSK# [002] 58 superficial bladder cancer 58 temsirolimus 58 multicentre randomized 58 Study Evaluating 58 TLK# 58 Emtriva Viread 58 TKB# 58 PEGylated interferon 58 IFN α 58 receiving INTRON 58 randomized Phase IIb 58 decitabine 58 ADVANCE PD 58 multicenter multinational 58 BAL# [002] 58 dyskinesia PD LID 58 MYDICAR ® 58 subcutaneously administered 58 RE LY 58 raltegravir 58 IMiDs R 58 Linagliptin 58 Bayer HealthCare Onyx Pharmaceuticals 58 tanespimycin 58 CG# [003] 58 carboplatin paclitaxel 58 anti PlGF 58 VQD 58 subcutaneous PRO 58 CLORETAZINE TM VNP#M 58 UPLYSO 58 pegylated interferon alpha 2a 58 phase IIb 58 afatinib 58 Civacir 58 RhuDex R 58 anticancer compound 58 Tipranavir 58 abacavir lamivudine 58 refractory chronic lymphocytic 58 Fludara 58 EURIDIS 58 #mg ritonavir 58 CALGB 58 CoFactor 58 protease inhibitors PIs 58 atrasentan 58 zileuton 58 randomized multicenter trial 58 rilpivirine 58 intravesical infusion therapy 58 conserved antigens NP 58 atacicept 58 phase Ib clinical 58 small molecule thrombopoietin 58 mcg albinterferon alfa 2b 58 limiting toxicity DLT 58 placebo controlled 58 tesmilifene 58 ADXS# 58 oral antidiabetic 58 Eluting Stent 58 proteasome inhibitor 58 Factor Xa inhibitor 58 Matrix Phase 2b 58 oral salmon calcitonin 58 Initiate Clinical Trial 58 Engerix B 58 interferon ribavirin 58 dose cohort 58 JAK1 58 metformin HCl 58 invasive candidiasis 58 Zenvia ™ 58 interferon beta 1b 58 Albuferon TM 58 fenretinide 58 MTP inhibitor 58 Tocilizumab 58 pharmacokinetic PK profile 58 pharmacodynamics PD 58 Clolar ® 58 depsipeptide 58 Nitazoxanide 58 Quinamed 58 Cardiotoxicity 57 LEVAQUIN ® 57 rifabutin 57 cyclophosphamide doxorubicin vincristine 57 Serious adverse reactions 57 ALN PCS 57 pharmacokinetic interactions 57 LIALDA 57 Naive Patients 57 investigational compound 57 ATL# [001] 57 hypoxia selective 57 midstage clinical 57 HCV protease 57 epirubicin cyclophosphamide 57 Staccato loxapine 57 gemcitabine Gemzar 57 PPAR gamma agonist 57 Combo Stent 57 randomized placebo controlled 57 NGX# 57 Oral Fingolimod 57 Randomized Phase II 57 Xcytrin R 57 mg QD 57 integrin inhibitor 57 ribavirin RBV 57 Triapine R 57 sustained virologic response 57 GAMMAGARD 57 oral nucleoside analogue 57 ZD# [001] 57 Phase IIIb 57 JAK2 inhibitor 57 PRECiSE 57 Plasmin 57 HDACi 57 Seliciclib 57 Allovectin 7 57 multi kinase inhibitor 57 Kahalalide F 57 recurrent glioma 57 Rilonacept 57 deCODE AF TM 57 multicenter placebo controlled 57 statin simvastatin 57 intravenously administered 57 FOLPI 57 TMC# [002] 57 MoxDuo TM IR 57 RoACTEMRA 57 postmenopausal osteoporotic women 57 pegylated interferon alfa 2b 57 leukotriene receptor antagonist 57 demonstrated antitumor activity 57 Ultratrace 57 Protelos 57 International Verapamil SR 57 plus prednisone 57 plasma kallikrein 57 alkylating agent 57 Bafetinib 57 multicenter dose escalation 57 tramiprosate Alzhemed TM 57 peg interferon 57 HDAC Inhibitor 57 Zolinza 57 AIR CF1 57 PEGylated anti 57 Selective Electrochemical Tumor Ablation 57 omega interferon 57 liposomal doxorubicin 57 APEX PD 57 SCY 57 latrepirdine 57 CRMD# 57 CAELYX 57 indibulin 57 CLARITY TIMI 57 fluticasone furoate 57 edoxaban 57 Ranolazine 57 topiramate Topamax 57 tubulin inhibitor 57 KNS # 57 evaluating Actimmune 57 confirmatory Phase III